TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02822599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiaStAP
Description: To decrease post-operative bleeding volume.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo consisting of normal saline 0.9%
Study: NCT03706872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care
Study: NCT02560155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin 2% nasal ointement
Description: Mupirocin nasal ointement 2x/d for 5 days preoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine sol 4%
Description: Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
Study: NCT04069026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2416964
Description: Oral application of study drug daily in a predefined dose escalation scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2416964
Description: Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
Study: NCT02622217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Study: NCT01508182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin tablets
Description: Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR tablets
Description: Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/metformin IR FDC tablets
Description: Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin tablets
Description: Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR tablets
Description: Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/metformin IR FDC tablets
Description: Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
Study: NCT01038609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study: NCT02560155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine sol 4%
Description: Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
Study: NCT00638456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide plus Prevacid
Description: Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus Prevacid
Description: Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
Study: NCT01038609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Extended Release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Extended Release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03762785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized Dexmedetomidine
Description: inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized Dexmedetomidine
Description: inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
Study: NCT02354599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT203 80 mg or matching Placebo
Description: MT203 80 mg or matching placebo injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT203 80 mg or matching Placebo
Description: MT203 80 mg or matching placebo injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT203 150mg or matching Placebo
Description: MT203 150mg or matching placebo injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT203 150mg or matching Placebo
Description: MT203 150mg or matching placebo injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT203 150mg or matching Placebo
Description: MT203 150mg or matching placebo injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT203 150mg or matching Placebo
Description: MT203 150mg or matching placebo injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT203 300 mg or matching placebo
Description: MT203 300 mg or matching placebo injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT203 300 mg or matching placebo
Description: MT203 300 mg or matching placebo injection
Study: NCT01089075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 20 mg po for 7 days (2 tablets)
Study: NCT03806075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Second generation sequencing
Description: Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 16s rRNA gene sequencing
Description: Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16s rRNA gene sequencing
Description: Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
Study: NCT00671437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT03879421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated corneal collagen cross linking
Description: This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated corneal collagen cross linking
Description: This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
Study: NCT03203733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooral™
Description: An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Oral cooling by ice chips or crushed ice or ice pop
Study: NCT01440881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: infuses at 0.01MCG/KG/min for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: infuses at 0.01MCG/KG/min for 48 hours
Study: NCT02999152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and urines samples
Description: For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and urines samples
Description: For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy.
Study: NCT03970616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg every 28 days
Study: NCT00634790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam XR
Description: Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
Study: NCT02880150

Intervention type: OTHER
Group type: OTHER
Intervention: Stress test

Intervention type: OTHER
Group type: OTHER
Intervention: Stress test
Study: NCT00242593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4 mg twice daily oral rosiglitazone or placebo pill for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone
Description: 4 mg twice daily oral rosiglitazone or placebo pill for 18 months
Study: NCT02726945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GID SVF-2
Description: The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GID SVF-2
Description: The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Control
Study: NCT01310829

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Physiological Measurements
Description: Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.

Intervention type: BEHAVIORAL
Intervention: Virtual Reality Scene Viewing
Description: Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
Study: NCT01608373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine injection
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal lidocaine irrigation group
Description: Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline injection
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Study: NCT03672786

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multicentrum
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multicentrum
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
Study: NCT02264080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL2014

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02784769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of skin autofluorescence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of skin autofluorescence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy collection
Study: NCT00785174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive pressure support ventilation
Description: noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive pressure support ventilation
Description: noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
Study: NCT03289117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel gel installation device procedure
Description: Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard procedure
Description: Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
Study: NCT01191346

Intervention type: OTHER
Intervention: 3T MRI
Description: 3T MRI in addition to standard 1.5T MRI for treatment planning
Study: NCT01720238

Intervention type: DRUG
Intervention: Entecavir
Description: 0.5mg qd

Intervention type: DRUG
Intervention: Lamivudine plus Adefovir Dipivoxil
Description: Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
Study: NCT01872013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT02356679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eupasidin-s Tab
Description: three times per day, 1 tab for each time, PO, during 2weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stillen Tab.
Description: three times per day, 1 tab for each time, PO, during 2weeks
Study: NCT02910102

Intervention type: DRUG
Group type: OTHER
Intervention: RVT-101 35 mg
Description: RVT-101 once daily, oral, 35-mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: RVT-101 35 mg
Description: RVT-101 once daily, oral, 35-mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo once daily, oral

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo once daily, oral
Study: NCT01005927

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructooligosaccharide
Description: Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fructooligosaccharide
Description: Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
Study: NCT00997360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKI-179
Study: NCT01179165

Intervention type: OTHER
Intervention: Diagnostic
Description: Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
Study: NCT01802307

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Study: NCT03496766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Tipifarnib 600 mg will be administered until progression
Study: NCT03570320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modification of opioid prescription method
Description: Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
Study: NCT04591236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain stimulation
Description: tDCS brain stimulation on leg motor areas was applied to Parkinson patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill gait training
Description: Treadmill gait training was applied to Parkinson patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill gait training
Description: Treadmill gait training was applied to Parkinson patients.
Study: NCT02048488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-011
Description: Number of cycles until progression or unacceptable toxicity develops.
Study: NCT01436266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg buccally 2 hours prior to procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: 2mg buccally 2 hours prior to procedure
Study: NCT02134730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRIENDS for life
Description: Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
Study: NCT03034902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined EEG and fNIRS
Description: The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany
Study: NCT04194125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.
Study: NCT02788058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TKI
Description: Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Hypofractionated Radiotherapy
Description: 40-45 Gy/5-15f
Study: NCT01181674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: sc injection
Study: NCT00673179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m\^2.
Study: NCT01181674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose
Description: oral administration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle therapy
Description: diet and exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral administration
Study: NCT01181674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose
Description: oral administration
Study: NCT00673179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m\^2/day.